Tesamorelin vs Hexarelin
Both Tesamorelin and Hexarelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
Tesamorelin
Evidence ATesamorelin (Egrifta)
An FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
View full Tesamorelin profile →Hexarelin
Evidence BHexarelin (HEX)
The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
View full Hexarelin profile →Side-by-Side
| Attribute | Tesamorelin | Hexarelin |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | FDA-approved for HIV-associated lipodystrophy | Not FDA-approved — research compound (cardioprotective signals investigated) |
| Typical Dose | 2 mg daily (subcutaneous) | 100 mcg, 1–2 times daily (subcutaneous) |
| Clinics Indexed | 178 | 41 |
| Categories | growth-hormone, fat-loss | growth-hormone, recovery |
Key reported benefits — Tesamorelin
- ✓Visceral fat reduction
- ✓Natural GH stimulation
- ✓Cognitive benefit
- ✓Lean mass
Key reported benefits — Hexarelin
- ✓Strongest GH spike of GHRPs
- ✓Cardioprotective signals
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.